JMNP/
Articles/
2504000490
  • Open Access
  • Review
Phytotherapy Targeting Rheumatoid Arthritis: A Clinically Based Approach
  • Georgeta Stefanovici Zugravu 1, 2,   
  • Anca Miron 1, *

Received: 01 Jan 2025 | Revised: 17 Mar 2025 | Accepted: 19 Mar 2025 | Published: 21 Mar 2025

Abstract

Rheumatoid arthritis is a chronic autoimmune-inflammatory disease characterized by joint destruction and physical disability. The present treatment options in rheumatoid arthritis include nonsteroidal anti-inflammatory drugs, glucocorticoids, and synthetic and biological disease-modifying antirheumatic drugs. However, all these classes of medications have disadvantages associated with severe adverse reactions, patients' low adherence to treatment, and numerous drug interactions. These drawbacks emphasize the need to identify novel anti-inflammatory agents to replace or support standard therapy and improve treatment compliance. This mini-review focuses on herbal preparations whose efficacy was evaluated in clinical trials. Extracts of various plant species (Tripterygium wilfordii Hook F, Paeonia lactiflora Pallas, Olea europea L., Silybum marianum (L.) Gaertn., Hippophaë rhamnoides L., Punica granatum L., Vaccinium macrocarpon Aiton) and powdered plant parts (Allium sativum L., Rosa canina L.) significantly improved the clinical parameters, disease activity indices, and biochemical markers in rheumatoid arthritis patients when they were administered as supportive therapy alongside the standard medication or, more rarely, as monotherapy. The bioactive compounds have been only partially identified and further research is required to fully elucidate the phytochemical profile of these herbal preparations. Although the clinical studies performed up to now support the benefits of herbal supplementation in rheumatoid arthritis, there is a strong need for more human trials to validate the efficacy and safety of herbal preparations.

References 

  • 1.
    Aletaha, D.; Neogi, T.; Silman, A.J.; et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581.
  • 2.
    Smolen, J.S.; Aletaha, D.; McInnes, I.B. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038.
  • 3.
    Moosavian, S.P.; Paknahad, Z.; Habibagahi, Z.; et al. The effects of garlic (Allium sativum) supplementation on inflammatory biomarkers, fatigue, and clinical symptoms in patients with active rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled trial. Phytother. Res. 2020, 34, 2953–2962.
  • 4.
    Wang, Z.; Zhao, F.; Wei, P.; et al. Phytochemistry, health benefits, and food applications of sea buckthorn (Hippophae rhamnoides L.): A comprehensive review. Front. Nutr. 2022, 9, 1036295.
  • 5.
    Trelle, S.; Reichenbach, S.; Wandel, S.; et al. Cardiovascular safety of non-steroidal anti- inflammatory drugs: Network meta-analysis. Br. Med. J. 2011, 342, c7086.
  • 6.
    Gabriel, S.E.; Jaakkimainen, L.; Bombardier, C. Risk for serious gastrointestinal complications related to use of NSAIDs. A meta-analysis. Ann. Intern. Med. 1991, 115, 787.
  • 7.
    Huerta, C.; Castellsague, J.; Varas-Lorenzo, C.; et al. NSAIDs and risk of ARF in the general population. Am. J. Kidney Dis. 2005, 45, 531.
  • 8.
    Murray, M.D.; Brater, D.C. Renal toxicity of the NSAIDs. Ann. Rev. Pharmacol. Toxicol. 1993, 33, 435.
  • 9.
    Edwards, J.E.; McQuay, H.J.; Moore, R.A. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. Pain 2004, 111, 286–296.
  • 10.
    Scheiman, J.M.; Hindley, C.E. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 2010, 32, 667–677.
  • 11.
    Krug, H.; Broadwell, L.K.; Berry, M.; et al. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. Clin. Ther. 2000, 22, 40–52.
  • 12.
    Del Rincón, I.; Battafarano, D.F.; Restrepo, J.F.; et al. Glucocorticoid dose thresholds associated with all‐cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014, 66, 264–272.
  • 13.
    Van Staa, T.P.; Laan, R.F.; Barton, I.P.; et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheumatol. 2003, 48, 3224–3229.
  • 14.
    Caramaschi, P.; Biasi, D.; Dal Forno, I.; et al. Osteonecrosis in systemic lupus erythematosus: An early, frequent, and not always symptomatic complication. Autoimmune Dis. 2012, 725249.
  • 15.
    Wilson, J.C.; Sarsour, K.; Gale, S.; et al. THU0172 Risk for Serious Adverse Events Associated with Oral Corticosteroid Therapy in Patients with Rheumatoid Arthritis: A Uk Population Based Study 2016. Ann. Rheum. Dis. 2016, 75, 246–247.
  • 16.
    Juge, P.A.; Lee, J.S.; Lau, J.; et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur. Respir. J. 2021, 57, 2000337.
  • 17.
    Gilani, S.T.A.; Khan, D.A.; Khan, F.A.; et al. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J. Coll. Physicians Surg. Pak. 2012, 22, 101–104.
  • 18.
    Shin, K.; Baek, H.J.; Kang, Y.M.; et al. Efficacy and safety of add‐on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. Int. J. Rheum. Dis. 2019, 22, 1115–1122.
  • 19.
    Aletaha, D.; Stamm, T.; Kapral, T.; et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational study. Ann. Rheum. Dis. 2013, 62, 944–951.
  • 20.
    Jiang, M.; Zha, Q.; He, Y.; et al. Risk factors of gastrointestinal and hepatic adverse drug reactions in the treatment of rheumatoid arthritis with biomedical combination therapy and Chinese medicine. J. Ethnopharmacol. 2012, 141, 615–621.
  • 21.
    Chen, Z.; Li, X.P.; Li, Z.J.; et al. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Int. Immunopharmacol. 2013, 15, 474–477.
  • 22.
    Hänninen, O.; Kaartinen, K.; Rauma, A.L.; et al. Antioxidants in vegan diet and rheumatic disorders. Toxicology 2000, 155, 45–53.
  • 23.
    Quinonez-Flores, C.M.; Gonzalez-Chavez, S.A.; Del Rio Najera, D.; et al. Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: A systematic review. Biomed. Res. Int. 2016, 097417.
  • 24.
    Fernández-Llanio Comella, N.; Fernández Matilla, M.; Castellano Cuesta, J.A. Have complementary therapies demonstrated effectiveness in rheumatoid arthritis? Reumatol. Clin. 2016, 12, 151–157.
  • 25.
    Efthimiou, P.; Kukar, M.; MacKenzie, C.R. Complementary and alternative medicine in rheumatoid arthritis: No longer the last resort! HSS J. 2010, 6, 108–111.
  • 26.
    Salaffi, F.; Ciapetti, A. Clinical disease activity assessments in rheumatoid arthritis. Int. J. Clin. Rheumatol. 2013, 8, 347–360.
  • 27.
    Duarte-García, A.; Leung, Y.Y.; Coates, L.C.; et al. Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report. J. Rheumatol. 2019, 46, 996–1005.
  • 28.
    Wells, G.; Becker, J.C.; Teng, J.; et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 2009, 68, 954–960.
  • 29.
    Seror, R.; Tubach, F.; Baron, G.; et al. Measure of function in rheumatoid arthritis: Individualised or classical scales? Ann. Rheum. Dis. 2010, 69, 97–101.
  • 30.
    Felson, D.T.; LaValley, M.P. The ACR20 and defining a threshold for response in rheumatic diseases: Too much of a good thing. Arthritis Res. Ther. 2014, 16, 101–106.
  • 31.
    Goldbach-Mansky, R.; Wilson, M.; Fleischmann, R.; et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 2009, 151, 229–240.
  • 32.
    Tao, X.; Younger, J.; Fan, F.Z.; et al. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 2002, 46, 1735–1743.
  • 33.
    Molnar, V.; Matišić, V.; Kodvanj, I.; et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int. J. Mol. Sci. 2021, 22, 9208.
  • 34.
    Ingegnoli, F.; Castelli, R.; Gualtierotti, R. Rheumatoid Factors: Clinical Applications. Dis. Markers 2013, 35, 727–734.
  • 35.
    Lv, Q.W.; Zhang, W.; Shi, Q.; et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): A randomised, controlled clinical trial. Ann. Rheum. Dis. 2015, 74, 1078–1086.
  • 36.
    Cibere, J.; Deng, Z.; Lin, Y.; et al. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: Reanalysis using logistic regression analysis. J. Rheumatol. 2003, 30, 465–467.
  • 37.
    Piao, X.; Zhou, J.; Xue, L. Triptolide decreases rheumatoid arthritis fibroblast-like synoviocyte proliferation, invasion, inflammation and presents a therapeutic effect in collagen induced arthritis rats via inactivating lncRNA RP11-83J16. 1 mediated URI1 and β-catenin signaling. Int. Immunopharmacol. 2021, 99, 108010.
  • 38.
    Shan, Y.; Zhao, J.; Wei, K.; et al. A comprehensive review of Tripterygium wilfordii hook. f. in the treatment of rheumatic and autoimmune diseases: Bioactive compounds, mechanisms of action, and future directions. Front. Pharmacol. 2023, 14.
  • 39.
    Luo, J.; Jin, D.-E.; Yang, G.-Y.; et al. Total glucosides of paeony for rheumatoid arthritis: A protocol for a systematic review. BMJ Open 2016, 6, e010116.
  • 40.
    Feng, Z.-T.; Xu, J.; He, G.-C.; et al. A systematic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis. Clin. Rheumatol. 2018, 37, 35–42.
  • 41.
    Huang, Y.; Wang, H.; Chen, Z.; et al. Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: A meta-analysis. Drug Des. Devel. Ther. 2019, 13, 1969–1984.
  • 42.
    Zhang, L.; Wei, W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol. Ther. 2020, 207, 107452.
  • 43.
    Čabarkapa, A.; Živković, L.; Borozan, S. Dry olive leaf extract in combination with methotrexate reduces cell damage in early rheumatoid arthritis patients—A pilot study. Phytother. Res. 2016, 30, 1615–1623.
  • 44.
    Nediani, C.; Ruzzolini, J.; Romani, A.; et al. Oleuropein, a bioactive compound from Olea europaea L., as a potential preventive and therapeutic agent in non-communicable diseases. Antioxidants 2019, 8, 578.
  • 45.
    Savairam, V.D.; Patil, N.A.; Borate, S.R.; et al. Allicin: A review of its important pharmacological activities. Pharmacol. Res. – Mod. Chin. Med. 2023, 8, 100283.
  • 46.
    Zugravu, G.S.; Pintilescu, C.; Cumpat, C.-M.; et al. Silymarin supplementation in active rheumatoid arthritis: Outcomes of a pilot randomized controlled clinical study. Medicina 2024, 60, 999.
  • 47.
    Wu, W.T.; Chen, Y.R., Lu, D.H.; et al. Silymarin modulates catabolic cytokine expression through Sirt1 and SOX9 in human articular chondrocytes. J. Orthop. Surg. Res. 2021, 16, 1–9.
  • 48.
    Gupta, O.P.; Sing, S.; Bani, S.; et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 2000, 7, 21–24.
  • 49.
    Saber, M.S.; Fahim, H.I.; Ahmed, O.M.; et al. Assessment of the preventive effects of Silybum marianum (L.) Gaertn. seeds hydroethanolic extract and silymarin on complete Freund’s adjuvant induced arthritis in Wistar rats. Ann. Phytomed. 2020, 9, 172–182.
  • 50.
    Olas B. The beneficial health aspects of sea buckthorn (Elaeagnus rhamnoides (L.) A. Nelson) oil. J. Ethnopharmacol. 2018, 213, 183–190.
  • 51.
    Zielińska, A.; Nowak I. Abundance of active ingredients in sea-buckthorn oil. Lipids Health Dis. 2017, 16, 95.
  • 52.
    Solà Marsiñach, M.; Cuenca A.P. The impact of sea buckthorn oil fatty acids on human health. Lipids Health Dis. 2019, 18, 145.
  • 53.
    Zugravu, G.S.; Dimitriu, D.C.; Ciobanu, C.P.; et al. Benefits of sea buckthorn fruit oil as adjuvant therapy in rheumatoid arthritis. Farmacia 2024, 72, 554–564.
  • 54.
    Zugravu, G.S.; Pintilescu, C.; Cumpat, C.-M.; et al. Sea buckthorn fruit oil supplementation in active rheumatoid arthritis: A focus on composite disease activity indices and EULAR response. Med. Surg. J. – Rev. Med. Chir. Soc. Med. Nat., Iasi 2024, 128, 422–436.
  • 55.
    Santa-Maria, C.; López-Enríquez, S.; Montserrat-de la Paz, S.; et al. Up-date on anti-inflammatory molecular mechanisms induced by oleic acid. Nutrients 2023, 15, 224.
  • 56.
    Passos, M.E.P.; Alves, H.H.O.; Momesso, C.M.; et al. Differential effects of palmitoleic acid on human lymphocyte proliferation and function. Lipids Health Dis. 2016, 15, 217.
  • 57.
    Talbot, N.A.; Wheeler-Jones, C.P.; Cleasby, M.E. Palmitoleic acid prevents palmitic acid-induced macrophage activation and consequent p38 MAPK-mediated skeletal muscle insulin resistance. Mol. Cell. Endocrinol. 2014, 393, 129–142.
  • 58.
    Devaraj, S.; Jialal, I. α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1125–1133.
  • 59.
    Bai, S.K.; Lee, S.J.; Na, H.J.; et al. β-Carotene inhibits inflammatory gene expression in lipopolysaccharide-stimulated macrophages by suppressing redox-based NF-κB activation. Exp. Mol. Med. 2005, 37, 323–334.
  • 60.
    Kawata, A.; Murakami, Y.; Suzuki, S.; et al. Anti-inflammatory activity of β-carotene, lycopene and tri-n-butylborane, a scavenger of reactive oxygen species. In Vivo 2018, 32, 255–264.
  • 61.
    Liao, P.C.; Lai, M.H.; Hsu, K.P.; et al. Identification of β-sitosterol as in vitro anti-inflammatory constituent in Moringa oleifera. J. Agric. Food Chem. 2018, 66, 10748–10759.
  • 62.
    Liu, R.; Hao, D.; Xu, W.; et al. β-Sitosterol modulates macrophage polarization and attenuates rheumatoid inflammation in mice. Pharm. Biol. 2019, 57, 161–168.
  • 63.
    Camillo, L.; Grossini, E.; Farruggio, S.; et al. Alpha-tocopherol protects human dermal fibroblasts by modulating nitric oxide release, mitochondrial function, redox status, and inflammation. Skin Pharmacol. Physiol. 2022, 35, 1–12.
  • 64.
    Ghavipour, M.; Sotoudeh, G.; Tavakoli, E.; et al. Pomegranate extract alleviates disease activity and some biomarkers of inflammation and oxidative stress in Rheumatoid Arthritis patients. Eur. J. Clin. Nutr. 2017, 71, 92–96.
  • 65.
    Golmei, P.; Kasna, S.; Roy, K.P.; et al. Review on pharmacological advancement of ellagic acid. J. Pharmacol. Pharmacother. 2024, 15, 93–104.
  • 66.
    Yeoh, N.; Burton, J.P.; Suppiah, P.; et al. The role of the microbiome in rheumatic diseases. Curr. Rheumatol. Rep. 2013, 15, 314.
  • 67.
    Thimóteo, N.S.B.; Iryioda, T.M.V.; Alfieri, D.F.; et al. Cranberry juice decreases disease activity in women with rheumatoid arthritis. Nutrition 2019, 60, 112–117.
  • 68.
    Mur, E.; Hartig, F.; Eibl, G.; et al. Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J. Rheumatol. 2002, 29, 678–681.
  • 69.
    Willich, S.N.; Rossnagel, K.; Roll, S.; et al. Rose hip herbal remedy in patients with rheumatoid arthritis – a randomised controlled trial. Phytomedicine 2010, 17, 87–93.
  • 70.
    Winther, K.; Apel, K.; Thamsborg, G. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial. Scand. J. Rheumatol. 2005, 34, 302–308.
Share this article:
Download PDF
DOI
10.53941/jmnp.2025.100007
Issue
Volume 2, Issue 1
How to Cite
Zugravu, G. S.; Miron, A. Phytotherapy Targeting Rheumatoid Arthritis: A Clinically Based Approach. Journal of Medicinal Natural Products 2025, 2 (1), 100007. https://doi.org/10.53941/jmnp.2025.100007.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2025 by the authors.